Consistent with our findings of frequent PAQR8 CN gain in therapy-resistant recurrent tumors in breast cancer patients and mouse models, we now provide the first in vivo evidence that PAQR8 plays a functional role in cancer and does so through its ability to confer a survival advantage on tumor cells subjected to different forms of therapy. This evidence concerns the gene PAQR8 and breast carcinoma.